Scarica l'app Stockscreener
17.95
5.84%
0.99
Dopo l'orario di chiusura:
17.95
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$16.96
Aprire:
$18.225
Volume 24 ore:
435.74K
Relative Volume:
0.59
Capitalizzazione di mercato:
$1.46B
Reddito:
$288.00K
Utile/perdita netta:
$-228.06M
Rapporto P/E:
-4.2235
EPS:
-4.25
Flusso di cassa netto:
$-168.82M
1 W Prestazione:
+6.91%
1M Prestazione:
+22.03%
6M Prestazione:
-4.32%
1 anno Prestazione:
+14.99%
Intervallo 1D:
$17.94
$18.44
Intervallo di 1 settimana:
$16.46
$18.44
Portata 52W:
$9.90
$27.20
Viridian Therapeutics Inc Stock (VRDN) Company Profile
Nome
Viridian Therapeutics Inc
Settore
Industria
Telefono
617.272.4600
Indirizzo
221 CRESCENT STREET, WALTHAM
Confronta VRDN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VRDN
Viridian Therapeutics Inc
|
17.95 | 1.38B | 288.00K | -228.06M | -168.82M | -4.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.95 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.39 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.64 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
575.42 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.83 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Viridian Therapeutics Inc Stock (VRDN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-19 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-11-25 | Iniziato | TD Cowen | Buy |
| 2024-09-11 | Reiterato | Needham | Buy |
| 2024-06-11 | Iniziato | Wolfe Research | Outperform |
| 2024-06-06 | Iniziato | Goldman | Buy |
| 2024-05-09 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2024-05-09 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2023-06-14 | Iniziato | BTIG Research | Buy |
| 2023-06-14 | Ripresa | Credit Suisse | Outperform |
| 2023-05-30 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-04-17 | Iniziato | Wells Fargo | Overweight |
| 2023-03-30 | Iniziato | Stifel | Buy |
| 2022-12-19 | Iniziato | Cowen | Outperform |
| 2022-12-19 | Iniziato | Needham | Buy |
| 2022-12-16 | Iniziato | Credit Suisse | Outperform |
| 2022-12-01 | Iniziato | H.C. Wainwright | Buy |
| 2022-06-23 | Iniziato | B. Riley Securities | Buy |
| 2021-11-18 | Iniziato | SVB Leerink | Outperform |
| 2021-10-12 | Iniziato | Evercore ISI | Outperform |
| 2021-01-25 | Iniziato | Ladenburg Thalmann | Buy |
Mostra tutto
Viridian Therapeutics Inc Borsa (VRDN) Ultime notizie
Is Viridian Therapeutics Inc. a good long term investmentOutstanding risk-reward balance - Autocar Professional
What drives Viridian Therapeutics Inc. stock priceFree Investment Community - jammulinksnews.com
What analysts say about Viridian Therapeutics Inc. stockOutperformance with explosive growth - jammulinksnews.com
Why Viridian Therapeutics Inc. stock attracts strong analyst attentionBreakout Level Watch - Newser
Viridian Therapeutics Inc. Stock Analysis and ForecastSuperior returns - Autocar Professional
Teacher Retirement System of Texas Decreases Stock Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
(VRDN) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Principal Financial Group Inc. Acquires 30,392 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
Viridian Therapeutics’ Veligrotug Shows Durable Proptosis Response in Phase 3 TED Trial - MSN
13 Best Low Priced Pharma Stocks to Buy Now - Insider Monkey
What makes Viridian Therapeutics Inc. stock price move sharplyFast Moving Stock Alerts - Newser
How Viridian Therapeutics Inc. stock performs during market volatilitySafety First Trading Signals - Newser
Evercore Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Cuts Target Price to $38 - 富途牛牛
Amalgamated Bank Has $34,000 Stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
Evercore ISI Lowers Viridian Therapeutics Price Target to $38 - AInvest
Viridian Therapeutics Sees Relative Strength Rating Improve To 79 - MSN
(VRDN) Investment Analysis - news.stocktradersdaily.com
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Viridian Therapeutics: Fueling R&D Breakthroughs Through Strategic Equity Incentives - AInvest
Is Viridian Therapeutics (NASDAQ:VRDN) A Risky Investment? - simplywall.st
(VRDN) On The My Stocks Page - news.stocktradersdaily.com
When (VRDN) Moves Investors should Listen - news.stocktradersdaily.com
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives $37.56 Average Target Price from Analysts - Defense World
Viridian Therapeutics’ SWOT analysis: promising TED treatment stock faces pivotal year - Investing.com
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Purchased by California State Teachers Retirement System - Defense World
Viridian Therapeutics: The Song Remains The Same (NASDAQ:VRDN) - Seeking Alpha
Transcript : Viridian Therapeutics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 08 - MarketScreener
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $2.22 Million Stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
Where are the Opportunities in (VRDN) - news.stocktradersdaily.com
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | VRDN Stock News - GuruFocus
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Viridian Therapeutics Inc Azioni (VRDN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.91%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):